15 completed, 3 recruiting, 2 terminated, 1 unknown. 22 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 22 | Completed 15, Recruiting 3, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 3 |
Follow Liposarcoma: new trials by email Literature Review of Liposarcoma trials Research Report on Liposarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism Ersodetug - Tumor Hyperinsulinism (Tumor HI) | Phase 3 | Recruiting | Rezolute | 16 | 2025-04-16 | 2026-09-28 |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin - Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 365 | 2024-09-11 | 2026-11-06 |
| Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma Brigimadlin - Liposarcoma, Dedifferentiated | Phase 3 | Completed | Boehringer Ingelheim | 138 | 2023-12-13 | 2026-01-09 |
| Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma Brigimadlin, Doxorubicin - Liposarcoma, Dedifferentiated | Phase 2 / Phase 3 | Completed | Boehringer Ingelheim | 400 | 2022-03-31 | 2026-03-02 |
| Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma RAIN-32, Trabectedin - Dedifferentiated Liposarcoma | Phase 3 | Terminated | Rain Oncology Inc | 175 | 2021-07-14 | 2025-01-14 |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma Surgery, Preoperative chemotherapy - Retroperitoneal Sarcoma, Liposarcoma | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 250 | 2021-01-20 | 2026-10-07 |
| Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin Trabectedin discontinuation, Trabectedin continuation - Leiomyosarcoma, Liposarcoma | Phase 3 | Withdrawn | Italian Sarcoma Group | 2019-02-28 | 2019-05-13 | |
| Selinexor in Advanced Liposarcoma Selinexor, Placebo - Dedifferentiated Liposarcoma | Phase 2 / Phase 3 | Completed | Karyopharm Therapeutics Inc | 342 | 2016-01-04 | 2023-01-23 |
| A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Olaratumab, Doxorubicin, Placebo - Soft Tissue Sarcoma | Phase 3 | Completed | Eli Lilly and Company | 509 | 2015-09-14 | 2025-07-15 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Trabectedin, Dacarbazine - Advanced or Metastatic Liposarcoma or Leiomyosarcoma | Phase 3 | Completed | Xian-Janssen Pharmaceutical Ltd. | 16 | 2012-08-07 | 2018-07-11 |
| Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer cyproheptadine hydrochloride, placebo - Cancer | Phase 3 | Terminated | University of South Florida | 22 | 2010-06-01 | 2015-07-02 |
| Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery - Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma | Phase 3 | Completed | Children's Oncology Group | 588 | 2007-02-05 | 2022-04-28 |
| Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma radiotherapy - Sarcoma | Phase 3 | Completed | Sheffield Teaching Hospitals NHS Foundation Trust | 216 | 2006-03-01 | 2021-03-18 |
| Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma doxorubicin hydrochloride, ifosfamide, adjuvant therapy - Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma | Phase 3 | Unknown | European Paediatric Soft Tissue Sarcoma Study Group | 250 | 2006-03-01 | 2013-08-12 |
| Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis conventional surgery, radiation therapy - Sarcoma | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 370 | 2004-08-01 | 2016-07-06 |
| Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma pegfilgrastim, doxorubicin hydrochloride, ifosfamide - Sarcoma | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 455 | 2003-04-01 | 2014-10-27 |
| Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma doxorubicin hydrochloride, ifosfamide - Sarcoma | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 780 | 1998-01-01 | 2012-01-20 |
| Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma doxorubicin hydrochloride, etoposide, ifosfamide - Sarcoma | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 340 | 1997-07-01 | 2013-09-17 |
| Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma filgrastim, doxorubicin hydrochloride, ifosfamide - Endometrial Cancer, Kidney Cancer | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 340 | 1996-04-01 | 2012-07-11 |
Showing 20 of 22. Sign in to see all of them.
Sarcoma (16) · Fibrosarcoma (13) · Leiomyosarcoma (13) · Hemangiosarcoma (11) · Histiocytoma, Malignant Fibrous (11) · Sarcoma, Synovial (10) · Neurofibrosarcoma (9) · Hemangiopericytoma, Malignant (7) · Malignant mesenchymal tumor (5) · Sarcoma, Alveolar Soft Part (5) · Rhabdomyosarcoma (4) · Chondrosarcoma, Extraskeletal Myxoid (3) · Dermatofibrosarcoma (3) · Sarcoma, Endometrial Stromal (3)
Neoplasms by Histologic Type (22) · Neoplasms, Adipose Tissue (22) · Neoplasms, Connective and Soft Tissue (22) · Neoplasms (20) · Neoplasms, Connective Tissue (16) · Neoplasms, Fibrous Tissue (15) · Neoplasms, Muscle Tissue (13) · Neoplasms, Nerve Tissue (12) · Histiocytoma (11) · Neoplasms, Vascular Tissue (11) · Nervous System Diseases (10) · Nervous System Neoplasms (10) · Peripheral Nervous System Neoplasms (10) · Neurofibroma (9) · Neuromuscular Diseases (9)
Doxorubicin (11) · Ifosfamide (9) · Radiotherapy (7) · Chemotherapy, Adjuvant (3) · Neoadjuvant Therapy (3) · Etoposide (2) · Filgrastim (2) · Trabectedin (2) · brigimadlin (2) · Brachytherapy (1) · Carboplatin (1) · Combined Modality Therapy (1) · Cyclophosphamide (1) · Cyproheptadine (1) · Dacarbazine (1)
European Organisation for Research and Treatment of Cancer - EORTC (6) · Boehringer Ingelheim (2) · National Cancer Institute (NCI) (2) · Alliance for Clinical Trials in Oncology (1) · Children's Oncology Group (1) · Eli Lilly and Company (1) · European Paediatric Soft Tissue Sarcoma Study Group (1) · Italian Sarcoma Group (1) · Karyopharm Therapeutics Inc (1) · Rain Oncology Inc (1) · Rezolute (1) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · Societe Internationale d'Oncologie Pediatrique (1) · University of South Florida (1) · Xian-Janssen Pharmaceutical Ltd. (1)
United Kingdom (13) · Canada (12) · United States (12) · France (10) · Germany (9) · Spain (9) · Belgium (8) · Denmark (7) · Italy (7) · Netherlands (7) · Australia (5) · Austria (5) · Sweden (5) · Switzerland (5) · Japan (4)
A.N. Van Geel, MD (1) · Aaron R Weiss (1) · Andrea Ferrari, MD (1) · Bernadette Brennan, MD (1) · Ian R. Judson, MA, MD, FRCP (1) · Jeffrey P. Krischer, PhD (1) · Joern Treuner, MD (1) · Laurence H. Baker, DO, FACOI (1) · M. C. G. Stevens, MD (1) · Martin Robinson, MD (1) · Max Van Noesel, MD, PhD (1) · Modesto Carli, MD (1) · Paul C. Lorigan, MD (1) · Penella J. Woll, MD, PhD (1)
PMID 17634494, PMID 20434400, PMID 22665534, PMID 22954508, PMID 24618336, PMID 24747207, PMID 28391003, PMID 28447475, PMID 29450452, PMID 30954717, PMID 31786124, PMID 32259228, PMID 32702309, PMID 32827353, PMID 33548339, PMID 33632930, PMID 34515544, PMID 34623899, PMID 34666214, PMID 35394800, PMID 36566574, PMID 36987836, PMID 37523624, PMID 38086314, PMID 38757485, PMID 39122389, PMID 41386267, PMID 42035475
2015 (2), U10CA098543 (2), 2023 (1), U10CA081920 (1), U10CA180820 (1), U10CA180830 (1), U10CA180886 (1)